US OptionsDetailed Quotes

RYTM241220P17500

Watchlist

0.92
0.000.00%

15min DelayClose Nov 27 16:00 ET

0.00High0.00Low

Rhythm Pharmaceuticals Stock Discussion

Stock_Drift

Nov 13 21:21

$Rhythm Pharmaceuticals (RYTM.US)$

Meltyy

May 16 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Moomoo AI

Feb 11 07:20

Rhythm Pharmaceuticals' high P/S ratio is alarming due to its lower forecast growth compared to the industry. Future revenues may not sustain the positive sentiment, risking shareholders' investments and potential investors may pay a high premium. Investors should note the company's 2 warning signs.

Optimistic Investors Push Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Up 26% But Growth Is Lacking

Moomoo AI

Dec 27, 2023 05:38

Rhythm Pharmaceuticals' high P/S ratio and unstable revenue growth could be alarming for investors. Given the weak revenue forecast, share prices may risk a decline. Investor caution is advised.

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 39%

Bigmoney Dreamer

Dec 14, 2023 13:02

$Rhythm Pharmaceuticals (RYTM.US)$ bought few time to move up ! 🤙🏻

Moomoo AI

Oct 9, 2023 15:10

The 18% share price drop appears severe in light of the firm's significant revenue growth. As Rhythm Pharmaceuticals' performance dips below the 2% loss averaged over the past five years, other factors may impact the stock's performance, carrying significant risks for investors.

Rhythm Pharmaceuticals (NASDAQ:RYTM Investor One-year Losses Grow to 18% as the Stock Sheds US$156m This Past Week

Carter West

Mar 13, 2023 05:17

Columns A list of companies with deposits in SVB

Based on comprehensive media reports, I compiled a list of some institutions with deposits in the bank for your reference. $SVB Financial (SIVB.US)$
ROKU: 26% cash, $487 million in Silicon Valley Bank. $Roku Inc (ROKU.US)$
BLOCKFI: According to a bankruptcy filing, BlockFi has $227 million in "unprotected" funds at Silicon Valley Bank, possibly in violation of U.S. bankruptcy law.
RBLX: Roblox says 5% of its $3 billion cash and securities balance is held by S...

Wildfire Prevention? Another bank shut down

BioPharm Insight US

Oct 31, 2022 10:58

Columns Weekly FDA Drug Pipeline Calendar (Oct 31- Nov 4)

Hello mooers, welcome to another week of the FDA calendar. Here are what happened last week and what's coming up this week.
Top Medical News of the Week
Merck Q3 earnings top Wall Street’s expectations
Merck stock surged within a buy zone Thursday after the pharma giant notched a third-quarter beat on particularly strong performances from Keytruda and Gardasil.
Revenue from blockbuster cancer drug Keytruda soared 20% during the quarter, leading a ...

Expand

No comment yet